VF
ZNTL icon

Virtu Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Virtu Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,973
Closed -$76K – 2138
2024
Q4 		$76K Buy
+24,973
New +$81.8K ﹤0.01% 1083
2024
Q3 		– Sell
-93,186
Closed -$381K – 1959
2024
Q2 		$381K Buy
+93,186
New +$1.04M 0.03% 524
2023
Q4 		– Sell
-16,223
Closed -$325K – 2080
2023
Q3 		$325K Buy
+16,223
New +$412K 0.03% 476
2021
Q1 		– Sell
-7,142
Closed -$371K – 2104
2020
Q4 		$371K Buy
+7,142
New +$322K 0.04% 546

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial's ZNTL Position: Q1 2025 in Review

Virtu Financial sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 24,973 shares — an estimated $76K sold.

Virtu Financial first reported a position in ZNTL in Q4 2020 and held it in 4 quarters. The position peaked at $381K in Q2 2024. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • Virtu Financial reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 24,973 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $76K.
  • Virtu Financial first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Virtu Financial's Zentalis Pharmaceuticals position peaked at $381K in Q2 2024.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.